PMID- 36443929
OWN - NLM
STAT- MEDLINE
DCOM- 20230227
LR  - 20230303
IS  - 1365-2982 (Electronic)
IS  - 1350-1925 (Linking)
VI  - 35
IP  - 3
DP  - 2023 Mar
TI  - Treatment outcomes in patients with globus: A randomized control trial of 
      psychoeducation, neuromodulators, and proton pump inhibitors.
PG  - e14500
LID - 10.1111/nmo.14500 [doi]
AB  - BACKGROUND: Globus is a persistent or intermittent nonpainful sensation of a lump 
      or foreign body, which markedly affect patient's quality of life. Treatment 
      options for globus are limited and unsatisfying. This study aims to compare the 
      effects of cognitive-behavioral-theory-based psychoeducation (CBT), 
      neuromodulators (NMD), and proton pump inhibitor (PPI) on treatment outcomes in 
      patients with globus. METHODS: Eligible patients were randomly received CBT, 
      0.5 mg flupenthixol and 10 mg melitracen; NMD, or omeprazole 20 mg; PPI, for 
      4 weeks. The primary endpoint was the reduction in symptom scores; Glasgow 
      Edinburgh Throat Scale (GETS). The secondary endpoints included treatment 
      efficacy on Reflux Symptom Index (RSI), Hospital Anxiety Depression Scale (HADS), 
      and quality of life (QoL) based on a 36-item short-form health survey (SF-36). 
      Treatment compliance and adverse effects were recorded. KEY RESULTS: Forty 
      patients were completed study. Baseline characteristics between the groups were 
      comparable. By the end of treatment, both CBT and NMD provided greater reduction 
      in GETS than PPI (CBT vs PPI; 6.46 +/- 8.56 vs 0.21 +/- 5.42; p = 0.031, NMD vs PPI; 
      6.92 +/- 9.85 vs 0.21 +/- 5.42; p = 0.036). The improvement of RSI, HADS, and SF-36 
      among the groups was similar. Neuromodulators caused more adverse events. 
      CONCLUSIONS & INFERENCES: Both CBT and NMD provided equally effective treatment 
      and better than PPI in patients with globus determined by the reduction in GETS. 
      The improvement in RSI, HADS, and QoL of the three groups was not different. 
      Given less of adverse effect than NMD, CBT should be considered as a substantial 
      treatment.
CI  - (c) 2022 John Wiley & Sons Ltd.
FAU - Poovipirom, Natthanan
AU  - Poovipirom N
AD  - Division of Gastroenterology, Department of Internal Medicine Faculty of Medicine 
      Siriraj Hospital, Mahidol University, Bangkok, Thailand.
FAU - Ratta-Apha, Woraphat
AU  - Ratta-Apha W
AD  - Department of Psychiatry, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Maneerattanaporn, Monthira
AU  - Maneerattanaporn M
AD  - Division of Gastroenterology, Department of Internal Medicine Faculty of Medicine 
      Siriraj Hospital, Mahidol University, Bangkok, Thailand.
FAU - Geeratragool, Tanawat
AU  - Geeratragool T
AD  - Division of Gastroenterology, Department of Internal Medicine Faculty of Medicine 
      Siriraj Hospital, Mahidol University, Bangkok, Thailand.
FAU - Chuenprapai, Pritsana
AU  - Chuenprapai P
AD  - Division of Gastroenterology, Department of Internal Medicine Faculty of Medicine 
      Siriraj Hospital, Mahidol University, Bangkok, Thailand.
FAU - Leelakusolvong, Somchai
AU  - Leelakusolvong S
AD  - Division of Gastroenterology, Department of Internal Medicine Faculty of Medicine 
      Siriraj Hospital, Mahidol University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20221128
PL  - England
TA  - Neurogastroenterol Motil
JT  - Neurogastroenterology and motility
JID - 9432572
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Neurotransmitter Agents)
SB  - IM
MH  - Humans
MH  - *Proton Pump Inhibitors
MH  - Quality of Life
MH  - *Gastroesophageal Reflux/diagnosis
MH  - Treatment Outcome
MH  - Neurotransmitter Agents
OTO - NOTNLM
OT  - globus
OT  - globus pharyngeus
OT  - neuromodulators
OT  - proton pump inhibitor
OT  - psychoeducation
EDAT- 2022/11/30 06:00
MHDA- 2023/03/03 06:00
CRDT- 2022/11/29 00:22
PHST- 2022/11/03 00:00 [revised]
PHST- 2022/07/22 00:00 [received]
PHST- 2022/11/09 00:00 [accepted]
PHST- 2022/11/30 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2022/11/29 00:22 [entrez]
AID - 10.1111/nmo.14500 [doi]
PST - ppublish
SO  - Neurogastroenterol Motil. 2023 Mar;35(3):e14500. doi: 10.1111/nmo.14500. Epub 
      2022 Nov 28.